SUMMARY
Pharma Compliance Latam – 2021 is a platform for industry leaders in the region to share experiences, knowledge and understand the trends that mark the future of this industry.
The environment has changed, the Regulations got modified and outside circumstances like the Covid, have forced us to improve on the run. We want to “touch base”, make a pause and for 2 days, share best practices and learn better tools to move in along the changes and updates.
Who will
you meet?
Officers
General Counsels
Directors
Vice Presidents
From these areas:
- Ethics and Compliance
- Corporate Responsibility
- Quality Assurance
- International Contracts
- Regulatory Compliance
- Corporate Compliance
- Legal Affairs
- Internal Audit
- Business Conduct
- Transparency Operations
- Private practice Lawyers
Speaker Board
Andres Vasquez Obando
Legal Compliance Director
Valentina Mainardi
General Manager
Elizabeth Rojas
CEO / GMPs, Audits & Regulatory Affairs
Alondra Diaz
Compliance VP
Renata Fidale
Executive Officer
Diogo Mota
Ethics and Compliance Associate Director
Jose Luis Robledo
Medical Director, Pharmacovigilance & Compliance Officer
Santiago Cal y Mayor
Compliance Director
Pedro Fontenele Pereira
Financial Controls & Compliance Head
Mariana Fiordilino
Senior Legal & Compliance Director
Maria del Carmen Ruiz
Head of Legal & Compliance
Marcela Inzunza
Head of Legal & Compliance for Chile & Cluster, Corp. Lawyer
Katia Rosenstein
Director of Compliance
Joelson Santos
Lawyer & Corporate Governance Professional
Claudia Correa de Miranda
Regulatory Affairs Head | Regulatory Compliance
Carlos Lanardonne
Head of BD, Strategic Alliances & Est. Medicines, Novartis South Cone
Adriana Fussuma
Head of Ethics, Risk and Compliance
Program at a Glance
Compliance in Pandemic times
Proper communication with Third Parties
Regulatory Open Table
The new On-line methods
Challenges for Multinationals
Compliance trends in Latam: Risk management
Risk profiling
Photo Gallery from Previous Events
Testimonials
-
”It was an excellent opportunity to hear what the authorities industry, even sometimes what our competitors or other providers have to say about the topic.”
Alison Bascou, Sr. Regulatory Director at BD, France
-
"I think it's being an interesting event. Wherever there's discussion at top level, wherever there's respect. wherever there's an open forum, science can advance. It's very important to keep patient's well-being in mind and I think this forum allows that."
Jaime Uribe, CEO At PROBIOMED
-
“The strength of the biosimilar industry in our region is very encouraging. It seems to me this event is the propitious forum to share experiences and it is great.”
Tammy Boggiano Ayo, Process Development Director at CIM, Cuba
-
“It showed a broad picture, from a highly technical perspective up to a commercial viewpoint. It is not easy to get that in such a short period of time.”
Santiago Salguero, Executive Director at Pharmaceutical Association of Ecuador
-
“For companies like those I work for, i.e. suppliers to the pharmaceutical industry, this has been a great opportunity to see our clients’ perspective and above all to identify the major trends determining the future of biosimilars.”
Mauricio Roberto Hernández Morales, Key Account and Business Developer Manager at BD Mexico